CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis by Fridman, V et al.
RESEARCH PAPER
CMT subtypes and disease burden in patients
enrolled in the Inherited Neuropathies Consortium
natural history study: a cross-sectional analysis
V Fridman,1 B Bundy,2 M M Reilly,3 D Pareyson,4 C Bacon,5 J Burns,6 J Day,7
S Feely,5,8 R S Finkel,9 T Grider,5 C A Kirk,2 D N Herrmann,10 M Laurá,3 J Li,11
T Lloyd,12 C J Sumner,12 F Muntoni,13 G Piscosquito,4 S Ramchandren,8,14 R Shy,5,8
C E Siskind,7 S W Yum,15,16 I Moroni,4 E Pagliano,4 S Zuchner,17 S S Scherer,16
M E Shy,5,8 on behalf of the Inherited Neuropathies Consortium
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
jnnp-2014-308826).
For numbered afﬁliations see
end of article.
Correspondence to
Dr Vera Fridman,
165 Cambridge St. Boston,
MA 02114, USA;
vfridman@partners.org
Received 25 July 2014
Revised 6 October 2014
Accepted 24 October 2014
To cite: Fridman V,
Bundy B, Reilly MM, et al.
J Neurol Neurosurg
Psychiatry Published Online
First: [please include Day
Month Year] doi:10.1136/
jnnp-2014-308826
ABSTRACT
Background The international Inherited Neuropathy
Consortium (INC) was created with the goal of obtaining
much needed natural history data for patients with
Charcot-Marie-Tooth (CMT) disease. We analysed clinical
and genetic data from patients in the INC to determine
the distribution of CMT subtypes and the clinical
impairment associated with them.
Methods We analysed data from 1652 patients
evaluated at 13 INC centres. The distribution of CMT
subtypes and pathogenic genetic mutations were
determined. The disease burden of all the mutations was
assessed by the CMT Neuropathy Score (CMTNS) and
CMT Examination Score (CMTES).
Results 997 of the 1652 patients (60.4%) received
a genetic diagnosis. The most common CMT subtypes
were CMT1A/PMP22 duplication, CMT1X/GJB1
mutation, CMT2A/MFN2 mutation, CMT1B/MPZ
mutation, and hereditary neuropathy with liability to
pressure palsy/PMP22 deletion. These ﬁve subtypes of
CMT accounted for 89.2% of all genetically conﬁrmed
mutations. Mean CMTNS for some but not all subtypes
were similar to those previously reported.
Conclusions Our ﬁndings conﬁrm that large numbers
of patients with a representative variety of CMT subtypes
have been enrolled and that the frequency of achieving
a molecular diagnosis and distribution of the CMT
subtypes reﬂects those previously reported. Measures of
severity are similar, though not identical, to results from
smaller series. This study conﬁrms that it is possible to
assess patients in a uniform way between international
centres, which is critical for the planned natural history
study and future clinical trials. These data will provide a
representative baseline for longitudinal studies of CMT.
Clinical trial registration ID number NCT01193075.
INTRODUCTION
Inherited peripheral neuropathies, collectively
known as Charcot-Marie-Tooth disease (CMT), are
among the most common inherited neurological dis-
eases with a prevalence of 1 in 2500 individuals.1
They encompass a clinically heterogeneous set of dis-
orders, and vary greatly in severity, spanning a spec-
trum from mildly symptomatic forms to those
resulting in severe disability. Patients typically present
with length-dependent weakness, atrophy and
sensory loss. CMT is also known as hereditary motor
and sensory neuropathy (HMSN). Hereditary motor
neuropathy (HMN) and hereditary sensory neur-
opathy (HSN) are related disorders and can also be
considered as part of the CMT family. Over 80 causa-
tive genes of CMT have been identiﬁed and many
more remain unknown.2 The natural history of these
various forms of CMTremains poorly understood, at
least in part, because these are rare disorders and
individual centres do not follow enough patients to
perform natural history studies. Furthermore, vali-
dated clinical instruments for measuring disease
severity have become available only recently and have
not yet been employed in many of the rare CMT
subtypes.
The Inherited Neuropathies Consortium (INC) is
a member of the Rare Diseases Clinical Research
Network (RDCRN) and was created in part to
perform natural history studies in CMT. The INC
currently includes 17 sites, (14 in the USA, and one
each in the UK, Italy and Australia). The natural
history study of the INC records clinical, electro-
physiological and genetic data from patients evalu-
ated. In this paper, we report patients evaluated
from the initial 13 sites (10 in the USA, and one
each in the UK, Italy and Australia) to ascertain the
subtype frequencies and the baseline clinical sever-
ity of each subtype using validated clinical outcome
measures. These quantiﬁable clinical data add to
the literature in providing the clinical severity of a
variety of CMT subtypes and also act as a baseline
for a longitudinal natural history study of CMT
subtypes, a prerequisite for clinical trials.
MATERIALS AND METHODS
Patient data for the INC natural history study of
CMT were collected on 1652 patients between
April 2009 and 2013 at 13 sites within the INC.
All patients were examined by clinical investigators
who had received training in the proper use of the
CMT Neuropathy Score (CMTNS), a 36 point com-
posite score based on patients’ symptoms (3 items),
signs (4 items) and neurophysiology (2 items). On
the basis of the CMTNS, patients can be classiﬁed
as having mild, moderate or severe disease (CMTNS
of <10, 11–20 or >20, respectively). Patients in the
severe category often require a walker or wheelchair.
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Patients with moderate scores frequently rely on ankle orthotics
but walk independently, and patients in the mild range have little
walking difﬁculty aside from occasional tripping. Participants
who did not have neurophysiology studies received a CMT
Examination Score (CMTES), which is the CMTNS without
neurophysiology. Therefore, the maximum CMTES is 28 rather
than 36.3
Patients were considered to have CMT if they had a sensory
and/or motor peripheral neuropathy and a family history of a
similar condition. Sensory and/or motor neuropathies were diag-
nosed based on the presence of length-dependent sensory loss
(small and large ﬁbre modalities), weakness and atrophy as well
as decreased deep tendon reﬂexes particularly at the Achilles
tendon. Nerve conduction studies were also used to conﬁrm
neuropathy in most patients. Patients without a family history
whose clinical history and electrophysiological ﬁndings were
consistent with CMT were also included. First-degree and
second-degree relatives of patients with a conﬁrmed genetic
mutation who demonstrated a similar clinical phenotype and
electrophysiological ﬁndings were assumed to have the same
mutation. Patients with a history of an acquired peripheral neur-
opathy were excluded.
Data collected included the type of CMT (CMT1, CMT2,
HMN, HSN, hereditary neuropathy with liability to pressure
palsy (HNPP)), subtype of CMT (CMT1A, CMT1B, etc) and
the pathogenic mutation if known. If the genetic diagnosis was
not known at the initial evaluation but was determined at a later
time point, the diagnosis was recorded and included in the ana-
lysis. Patients’ CMTNS or CMTES were recorded at each visit.
If patients did not undergo electrophysiology at a particular
visit, the CMTES was obtained alone. Standard methods were
used for all electrophysiology, and all sensory responses were
antidromic. A Clinical Laboratory Improvement Amendments
(CLIA) certiﬁed laboratory in the USA or an equivalent certiﬁed
testing facility outside of the USA performed all genetic testing.
All sites participating in protocol 6601 received Institutional
Review Board (IRB)/Ethics Board approval for the study. All
patients or their guardian signed consent forms. This trial was
registered at clinicaltrials.gov (ID number NCT01193075).
RESULTS
Distribution of patients
Baseline data were obtained from the initial 1652 patients from
protocol 6601. Four hundred and twenty-three participants
were 18 years of age or less. In total, 1427 patients were given a
clinical diagnosis of CMT. Of those patients in whom a subtype
of CMTwas speciﬁed, 910 were classiﬁed as having CMT1, 237
as having CMT2, 37 as having CMT4 (recessive demyelinating
or axonal forms of CMT), 107 as having CMT1X, 47 as having
HMN, 53 as having HSN and 36 as having HNPP (ﬁgure 1).
997 patients (60.4% of total patients enrolled) received a
genetic diagnosis. Of the total patients with CMT1, 836
(91.2%) received a genetic diagnosis. In contrast, only 43% of
patients with CMT2 received genetic conﬁrmation.
The most common genetic diagnoses for our patients were
CMT1A (PMP22 duplication), CMT1X (GJB1 mutation),
CMT2A (MFN2 mutation), CMT1B (MPZ mutation) and
HNPP (PMP22 deletion; table 1). These ﬁve subtypes of CMT
accounted for 89.2% of all of the genetically conﬁrmed muta-
tions. The remaining subtypes accounted for <1% each, with
the exception of HSN1, which accounted for 2.5% of patients
with a known genetic diagnosis (table 1). The relatively high
number of patients with HSN1 results from the large number of
patients enrolled at a single centre (National Hospital for
Neurology and Neurosurgery, UK). CMT1A comprised 67.5%
of patients with a known genetic diagnosis and 36.9% of total
patients. Among patients with CMT2, 29.5% had CMT2A.
Three patients had mutations in multiple genes.
Patient impairment
Baseline CMTNS (table 2, see online supplementary tables S1
and S2) and CMTES were available for 906 and 1316 patients,
respectively. The mean CMTNS for CMT1A was 13.7, which is
38% of the total score of 36 points, and is similar to what has
been reported in other series.4–6 The mean CMTES for
CMT1A was 9, which is 32% of the total score of 28. The
mean CMTNS for all patients with CMT1X was 13, and for
male patients only was 15.9. This is in the range of 11–16 as
previously reported for males in their second and third decades
of life.7 However, there were some unexpected ﬁndings for
patients with CMT1B and CMT2A, two of the other common
subtypes of CMT. The mean CMTNS for CMT2A—14.3—was
much lower than the value of 21 reported previously.8 The
mean and SD (13.7, SD 7.7) of the CMTNS for CMT1B were
similar to those of CMT1A (13.7, SD 6.5). Previous reports of
CMT1B have emphasised phenotypic differences in childhood
versus adult onset forms of the disease such that we would have
predicted a much wider SD in CMT1B even if their mean
CMTNS were similar.9 10
A newer version of the CMTNS, CMTNSv2, was developed
and validated in 2011 to make the CMTNS more sensitive to
change over time. We compared the CMTNS and CMTNSv2
baseline values in patients with CMT1A, who comprised our
largest subtype and have an identical genetic cause (the duplica-
tion of PMP22).11 12 The mean/SD was 14.7/3.6 (n=54) and
13.5/3.6 (n=271) for CMTNS versions 1 and 2, respectively.
The mean/SD was 9/2.8 (n=53) and 8.5/2.8 (n=462) for
CMTES versions 1 and 2, respectively.
CMT impairment is known to increase with age.13 This is
also evident in our patients with mean CMTNS increasing by
0.124 points for every additional year of age. To determine
whether the age of the patients we evaluated was affecting our
Figure 1 Distribution of clinically determined Charcot-Marie-Tooth
(CMT) subtypes.
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baseline scores, we evaluated the mean ages of patients with the
four most common subtypes. The mean ages/SD for CMT1A
(35/20), CMT1B (40/20), CMT2A (32/20) and CMT1X (39/17)
were similar. We additionally adjusted the mean CMTNS for age
and gender and found that while both variables were statistically
signiﬁcant, the mean CMTNS were not signiﬁcantly altered nor
the variance in scores signiﬁcantly decreased for the common
mutations (see online supplementary table S3). The differences
between the CMTNS and CMTES of different CMT subtypes
are therefore unlikely to be due to the age of the patients.
We next investigated whether different sites obtained similar
CMTNS and CMTES for patients with the most common sub-
types—CMT1A, CMT1B, CMT1X and CMT2A (table 3 and
see online supplementary table S4). We compared the results
Table 2 CMTNS for common mutations
CMT subtype
(mutation)
Mean
CMTNS (n) SD
Mean CMTNS
adjusted for
age and
gender Previous reports
CMT1A
(PMP22 dup)
13.7 (324) 6.5 13.6 13.2–14.6
(Shy et al;4
Pareyson et al5)
CMT1X (GJB1) 13 (53) 6.8 15 11–16, 2nd–3rd
decades (Shy et al;7
Siskind et al30)
CMT2A (MFN2) 14.3 (42) 8.7 12.6 21 (Feely et al8)
CMT1B (MPZ) 13.7 (42) 7.7 13.4
HNPP (PMP22) 4.5 (12) 2.1
The diseases and genes are named according to OMIM (http://www.ncbi.nlm.nih.gov/
Omim/) and HUGO (http://www.genenames.org/), respectively.
CMT, Charcot-Marie-Tooth; CMTNS, CMT Neuropathy Score; dup, duplicate; HNPP,
hereditary neuropathy with liability to pressure palsy.
Table 3 Mean CTMNS for individual sites
Site Mean CMTNS/SD (n)
CMT1A CMT1B CMT2A CMT1X
London 14.7/6.4 (38) 19.8/8.6 (5) 17.5/9.1 (8) 14.1/4.1 (14)
Milan 9/6.2 (20) 10.6/6.5 (5) 17 (1) 10.5/8.1 (4)
Detroit 13.7/6.9 (135) 12/7.5 (19) 15.4/9.9 (17) 14.6/8.2 (23)
Iowa 12.5/5.1 (33) 14/5.6 (3) 16/7.4 (6) 8.8/6.7 (4)
All others 14.4/6.1 (93) 15.4/8 (10) 8.5/5.2 (10) 9.9/4.2 (8)
CMT, Charcot-Marie-Tooth; CMTNS, CMT Neuropathy Score.
Table 1 Frequency of CMT subtypes
CMT subtype (mutation) n
Patients with genetic
diagnosis (n=997; %)
Total patients
(n=1652; %)
Total patients reported in prior studies
at WS (n=787; %) and L (n=425; %)10 14
Frequency of common CMT subtypes
CMT1A (PMP22dup) 614 61.6 37.2 36.9 WS/39.5 L
CMT1X (GJB1) 107 10.7 6.5 10.2 WS/10.8 L
CMT2A (MFN2) 70 7.0 4.2 2.7 WS/2.8 L
CMT1B (MPZ) 67 6.7 4.1 5.7 WS/3.1 L
HNPP (PMP22 del) 31 3.1 1.9 6.1 WS/5.7 L
Total 889 89.2 53.8 61.5 WS/62.5 L
Frequency of rare CMT1 subtypes
CMT1C (LITAF) 2 0.20 0.12 0.6 WS/0.9 L
CMT1D (EGR2) 1 0.10 0.06 0.1 WS
CMT1E (PMP22) 17 1.7 1.0 0.6 WS/1.4 L
CMT1F (NEFL) 4 0.40 0.24 0.5 L
Frequency of rare CMT2 subtypes
CMT2C (TRPV4) 3 0.30 0.18 0.7 L
CMT2D (GARS) 2 0.20 0.12 0.4 WS
CMT2E (NEFL) 7 0.70 0.42 0.5 WS
CMT2K (GDAP1) 3 0.30 0.18 0.6 WS
Frequency of CMT4 subtypes
CMT4A (GDAP1) 6 0.60 0.36 0.1 WS/0.5 L
CMT4B1 (MTMR2) 2 0.20 0.12 0.2 L
CMT4C (SH3TC2) 14 1.4 0.85 0.4 WS/1.2 L
CMT4F (PRX) 3 0.30 0.18 0.1 WS
CMT4H (FGD4) 1 0.10 0.06
CMT4J (FIG4) 4 0.40 0.24 0.3 WS
AR CMT2A (LMNA) 2 0.2 0.12
Frequency of HMN subtypes
HMN2B (HSPB1) 7 0.70 0.42 0.5 L
HMN2A (HSPB8) 1 0.10 0.06
HMN5A (BSCL2) 5 0.50 0.30 0.2 L
Frequency of HSN subtypes
HSN1 (SPTLC1) 24 2.4 1.5
The diseases and genes are named according to OMIM (http://www.ncbi.nlm.nih.gov/Omim/) and HUGO (http://www.genenames.org/), respectively.
AR, Autosomal Recessive; CMT, Charcot-Marie-Tooth; del, deletion; dup, duplicate; HMN, hereditary motor neuropath; HNPP, hereditary neuropathy with liability to pressure palsy;
HSN, hereditary sensory neuropathy; L, London; WS, Wayne State.
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from each of the four sites that had evaluated the largest
numbers of patients, and pooled results from the remaining sites
to minimise the effects from individual sites that had evaluated
fewer patients. A statistically signiﬁcant intersite variability in
CMTNS was detected among sites for the common subtypes of
CMT (p<0.0001). This signiﬁcant difference was completely
eliminated, however, by excluding the Milan site. These results
were not altered by adjusting for age and gender (see online sup-
plementary table S3).
Rare forms of CMT
To date, we have collected data on 78 patients with rarer forms
of CMT, including subtypes of CMT1, CMT2 and CMT4 (here
considered to be all recessive forms), HMN and HSN. Speciﬁc
characteristics of these patients are provided in online
supplementary tables S1 and S2.
DISCUSSION
Genetic distribution of CMT in the INC
Our data are from over 1650 patients with various forms of
CMT; the largest collection of patients with CMT reported to
date. As the data come from multiple sites, we compared our
results with what has been previously reported from single sites
or smaller series (see online supplementary tables S5 and S6).
These comparisons must be interpreted cautiously, however, as
the data presented in online supplementary table S5 include
populations from varied geographical regions. Furthermore, the
way in which CMTwas deﬁned and classiﬁed differed between
the various series. The largest single centre studies of CMT
include Detroit,10 London,14 France15 and Germany.16 In all
centres, CMT1A was, by far, the most common form of CMT,
followed by CMT1X, HNPP, CMT1B and CMT2A. These ﬁve
diagnoses cumulatively accounted for 89% of all genetic diagno-
ses in our series, similar to previous studies (91–94%). The
remaining genes tested accounted for less than 2.4% of each of
the positive genetic diagnoses. Many of the previously published
data come from single centres in the USA, the UK and northern
Europe.10 14–17 Since most INC sites are located within these
regions and many American and Australian ancestors are
from Northern Europe, it is not surprising that our results are
similar. The distribution of subtypes, varies in different
geographical regions, such as Greece,18 Norway,19 Spain20 and
Japan,21 and may differ even more where autosomal recessive
forms of CMT are more common22 (see online supplementary
tables S5 and S6).
In our current series, 60.4% of patients enrolled obtained a
genetic diagnosis, a similar value to the 54–67% observed in
other large series from the US and Northern Europe (see online
supplementary table S5). Our results were also similar to those
of previously published studies in that CMT1 was more
common in our patient population than CMT2 and had higher
genetic testing success rates (91% of patients with CMT1
received a genetic diagnosis versus only 43% of patients with
CMT2). The success rate for genetic diagnosis in CMT1 was
higher than that reported by the London group (84%)23 and
lower than that in the Detroit series (98%).10 The variation in
these values most likely reﬂects a referral bias, as some centres
may selectively see more patients in whom common mutations
have already been excluded. Our diagnostic hit rates were also
higher than those in which patients were not evaluated in CMT
centres,14 16 24 conﬁrming that making a genetic diagnosis is
more likely for patients evaluated in centres with expertise in
CMT.
CMTNS and outcome measures
A unique feature of our data is that it includes clinical outcome
measures such as the CMTNS, CMTNSv2 and CMTES for all
patients. Thus, we are recording the frequency of different gen-
otypes as well as recording quantiﬁed impairment scores for all
patients in a standardised fashion. We believe that these data are
useful not only in deﬁning the severity of each subtype but also
as a baseline for longitudinal natural history studies of various
subtypes of CMT. With regard to the speciﬁc outcome mea-
sures, the CMTNS3 and the CMTNSv223 have been validated,
and both are the currently suggested outcome measures for
CMT by the National Institutes of Neurological Diseases and
Stroke (NINDS) Common Data Elements resource guide. The
CMTNS has been shown to correlate well with other measures
of disability including the ambulation index, self-assessment and
hand function questionnaires, the Nine-Hole Peg Test, and the
neuropathy impairment score.3 Nevertheless, we recognise that
there are potential limitations for the CMTNS and CMTNSv2
in natural history investigations. Recent Italian/UK5 and
American6 clinical trials of ascorbic acid treatment for CMT1A
were not able to detect signiﬁcant progression with the CMTNS
over a 2-year period. Although the CMTNSv2 has been
designed to be more sensitive to change than the CMTNS,23
and has subsequently undergone Rasch analysis to further
improve its sensitivity,25 it has not yet been tested in longitu-
dinal studies. The INC is continuing to develop outcome mea-
sures including a paediatric instrument, the CMT Pediatric Scale
(CMTPedS),26 patient-reported disability score,27 CMT-speciﬁc
quality of life instruments for adults and children, and impair-
ment scores for infants. We expect data from these measures to
be increasingly available within the INC such that investigators
will be able to compare these instruments with the CMTNS in
future studies.
Our ﬁndings did show a signiﬁcant intersite variability in the
CMTNS; however, this variability was largely eliminated by
excluding patients from one centre where patients had received
lower scores. Investigators in the INC have been cross-trained
on common patients, have taken online training courses in the
performance of the CMTNS, and use standardised questioning
and examination techniques to ensure that evaluations of
patients at one centre will be similar to those at other sites.
Inter-rater variability has also been evaluated, showing a correl-
ation coefﬁcient between the total CMTNS for two examiners
of 0.98 for CMTNS and 0.97 for CMTNv2 (p<0.01).3 23
We therefore suspect that the difference in scoring at the Milan
site reﬂects the still low number of patients recruited, allowing
for large families with mild phenotypes to have a disproportion-
ate impact on the ﬁndings. Nevertheless, the differences
between sites also emphasise the need for continued training to
ensure that differences in methodology do not unduly inﬂuence
the natural history studies.
Site-speciﬁc scoring
The overall CMTNS, CMTNSv2 and CMTES from INC sites
for CMT1A were similar to what has been reported from single
centres, which suggests that sites were evaluating a representa-
tive group of patients.4–6 Similarly, scores for CMT1X were
similar to what has been reported.7 The scores for CMT1B and
CMT2A, however, differed from prior studies. Both the mean
CMTNS for CMT1B and SD of 7.7 were similar to those
of CMT1A (13.7 and 6.5). Previous reports on CMT1B have
emphasised phenotypic differences between early and adult
onset forms of disease, such that we would have predicted a
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much wider SD in patients with CMT1B even if their mean
CMTNS were similar.9 10 The mean CMTNS for CMT2A of
14.3 was similar to that for CMT1A and much lower than the
value of 21 reported previously.8 The differences in CMT1A
and CMT1X compared with CMT1B and CMT2A are probably
related, at least in part, to differences in their pathogenesis.
Mutations in CMT1A are all caused by the same duplication of
PMP22 on chromosome 1711 12 such that most patients have a
similar phenotype.28 More than 400 reported GJB1 mutations
that cause CMT1X have been reported.29 Affected males with
both point mutations and deletions in the GJB1 gene demon-
strate a similar, age-related phenotype, suggesting a loss of func-
tion mechanism of disease.7 Therefore, most male patients with
CMT1X would be predicted to have a CMTNS similar to what
has been previously reported. In contrast, the phenotypes of
both CMT1B and CMT2A are known to vary depending on the
particular mutation. Patients with CMT1B typically have a
severe neuropathy with onset in infancy or an onset in adult-
hood that may be much milder.9 10 Most MFN2 disease causing
mutations cause a severe neuropathy in which patients become
wheelchair users by young adulthood.8 The current study did
not include young children who are assessed using the
CMTPedS, and it is likely that participants with the most severe
phenotypes were therefore under-represented. In addition, there
may be variability in the distribution of patients in speciﬁc
clinics that affects our overall scores. This is particularly likely as
the total number of patients with CMT1B and CMT2A was 67
and 70 patients, respectively, and when this is divided into 13
centres, it is possible that any 1 centre may be enrolling a number
of patients from an individual family rather than multiple index
cases. For example in the CMT1B cohort, the mean CMTNS in
the London site was 19.8 compared with the Detroit site of 12.
In the London site, most patients were enrolled from a large indi-
vidual family with very severe early onset CMT1B. As the enrol-
ment of these two subtypes increases, we may get a better picture
of the true impairment in these two subtypes of CMT. There is
also the added complication in CMT2A that it is sometimes difﬁ-
cult to be sure a mutation is pathogenic using current validation
techniques. As we improve our ability to validate pathogenic
mutations, we may ﬁnd that some of the patients with milder
CMT2A harbour mutations in different genes and this may have
skewed the CMTNS.
Challenges with rare forms of CMT
A major goal of the INC is to increase our enrolment of patients
who have rare forms of CMT, so that we can generate natural
history data. We collected data on 78 patients with rare forms
of CMT, but this breaks down into just a few patients per geno-
type. This is a good start, but we need to evaluate more patients
to deﬁne the natural history of the rare forms of CMT. To
capture this group of patients, we need to obtain data from
regions such as North Africa where up to 40% of patients with
CMTare reported to have autosomal recessive inheritance.22
Author afﬁliations
1Departments of Neurology, Massachusetts General Hospital, Boston, Massachusetts,
USA
2University of South Florida Epidemiology Center, Tampa, Florida, USA
3MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK
4Departments of Neurology, IRCCS Foundation, Carlo Besta Neurological Institute,
Milan, Italy
5Departments of Neurology, University of Iowa Hospitals and Clinics, Iowa City,
Iowa, USA
6Departments of Neurology, University of Sydney & Children’s Hospital, Sydney,
Australia
7Departments of Neurology, Stanford University, Stanford, California, USA
8Departments of Neurology, Wayne State University, Detroit, Michigan, USA
9Departments of Neurology, Nemours Children’s Hospital, Orlando, Florida, USA
10Departments of Neurology, University of Rochester, Rochester, New York, USA
11Departments of Neurology, Vanderbilt University, Nashville, Tennessee, USA
12Departments of Neurology, John Hopkins University, Baltimore, Maryland, USA
13Departments of Neurology, UCL Institute of Child Health & Great Ormond Street
Hospital, London, UK
14Departments of Neurology, University of Michigan, Ann Arbor, Michigan, USA
15Departments of Neurology, Children’s Hospital of Philadelphia, Philadelphia,
Pennsylvania, USA
16Departments of Neurology, Hospital of the University of Pennsylvania, Philadelphia,
Pennsylvania, USA
17Departments of Neurology, Center for Human Molecular Genomics, University of
Miami, Miami, Florida, USA
Acknowledgements This INC is a part of the NIH Rare Diseases Clinical Research
Network (RDCRN). The authors would like to thank all the patients who participated
in the INC and their families. Without whom this study would not be possible. They
would also like to thank the people working at INC sites who contributed to this
study. These include Julian Blake, Betsy Burgos, Daniela Calabrese, Vinay Chaudhry,
David Cornblath, Katy Eichinger, Tim Estilow, Claudia Gandioli, Audra Hamilton,
Allan M Glanzman, Ahmet Hoke, Andrea Kelley, Livija Medne, Manoj Menezes,
Sinead Murphy, Jillian Olsen, Giuseppe Piscosquito, Alex Rossor, Oranee
Sanmaneechai, Anna Sorey, Mariola Skorupinska, Janet Sowden and Andrea
Swenson.
Contributors VF wrote the ﬁrst draft of the manuscript and collected and analysed
data. BB performed statistical analysis for the study. MMR and MES were involved in
the study conception, collected and analysed data and edited drafts of the
manuscript. CAK managed the data and edited drafts of the manuscript. SZ
contributed to genetic analysis for this manuscript. SSS collected data, helped edit
drafts of the manuscript and contributed tables to the manuscript. DP collected and
analysed data and edited drafts of the manuscript. JB, JD, RSF, DNH and ML
collected data and edited drafts of the manuscript. CB, SF, TG, JL, TL, CJS, FM, GP,
SR, RS, CES, SWY, IM and EP collected data.
Funding Funding and/or programmatic support for this project has been provided
by U54NS065712 from the National Institutes of Neurological Diseases and Stroke
(NINDS) and the NIH Ofﬁce of Rare Diseases Research (ORDR) at the National
Center for Advancing Translational Sciences (NCATS). The INC also receives support
from the Muscular Dystrophy Association (MDA) and the Charcot Marie Tooth
Association (CMTA). Additional support for this study includes the NINDS grant
R01NS066927 and Vanderbilt Institute for Clinical and Translational Research fund
VR1687 to JL. Part of this work was undertaken at University College London
Hospitals/University College London, which received a proportion of funding from
the Department of Health’s National Institute for Health Research Biomedical
Research Centres funding scheme.
Competing interests None.
Ethics approval University of Iowa IRB and Ethics Board.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement VF had full access to the data, and if requested, will
provide access to the data on which the manuscript was based to the editors.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin Genet
1974;6:98–118.
2 Rossor AM, Polke JM, Houlden H, et al. Clinical implications of genetic advances in
Charcot-Marie-Tooth disease. Nat Rev Neurol 2013;9:562–71.
3 Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy
score as a measure of disability. Neurology 2005;64:1209–14.
4 Shy ME, Chen L, Swan ER, et al. Neuropathy progression in Charcot-Marie-Tooth
disease type 1A. Neurology 2008;70:378–83.
5 Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth
disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
Lancet Neurol 2011;10:320–8.
6 Lewis RA, McDermott MP, Herrmann DN, et al. High-dosage ascorbic acid
treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized,
double-masked, controlled trial. JAMA Neurol 2013;70:981–7.
Fridman V, et al. J Neurol Neurosurg Psychiatry 2014;0:1–6. doi:10.1136/jnnp-2014-308826 5
Neurogenetics
group.bmj.com on February 6, 2015 - Published by http://jnnp.bmj.com/Downloaded from 
7 Shy ME, Siskind C, Swan ER, et al. CMT1X phenotypes represent loss of GJB1 gene
function. Neurology 2007;68:849–55.
8 Feely SM, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in
most patients with CMT2A. Neurology 2011;76:1690–6.
9 Shy ME, Jani A, Krajewski K, et al. Phenotypic clustering in MPZ mutations. Brain
2004;127:371–84.
10 Saporta AS, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and
genetic testing strategies. Ann Neurol 2011;69:22–33.
11 Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated
with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219–32.
12 Timmerman V, Nelis E, Van Hul W, et al. The peripheral myelin protein gene
PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication.
Nat Genet 1992;1:171–5.
13 Shy M, Lupski JR, Chance PF, et al. The hereditary motor and sensory neuropathies:
an overview of the clinical, genetic, electrophysiologic and pathologic features. In: Dyck
PJ TP, ed. Peripheral neuropathy. 4th ed. Philadelphia: WB Saunders, 2005:1623–58.
14 Murphy SM, Laura M, Fawcett K, et al. Charcot-Marie-Tooth disease: frequency of
genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry
2012;83:706–10.
15 Latour P, Gonnaud PM, Ollagnon E, et al. SIMPLE mutation analysis in dominant
demyelinating Charcot-Marie-Tooth disease: three novel mutations. J Peripher Nerv
Syst 2006;11:148–55.
16 Gess B, Schirmacher A, Boentert M, et al. Charcot-Marie-Tooth disease: frequency
of genetic subtypes in a German neuromuscular center population. Neuromuscul
Disord 2013;23:647–51.
17 Murphy SM, Laura M, Reilly MM. DNA testing in hereditary neuropathies. Handb
Clin Neurol 2013;115:213–32.
18 Karadima G, Floroskuﬁ P, Koutsis G, et al. Mutational analysis of PMP22, GJB1 and
MPZ in Greek Charcot-Marie-Tooth type 1 neuropathy patients. Clin Genet
2011;80:497–9.
19 Braathen G, Sand J, Lobato A, et al. Genetic epidemiology of Charcot-Marie-Tooth
in the general population. Eur J Neurol 2011;18:39–48.
20 Sivera R, Sevilla T, Vilchez JJ, et al. Charcot-Marie-Tooth disease: genetic and
clinical spectrum in a Spanish clinical series. Neurology 2013;81:
1617–25.
21 Abe A, Numakura C, Kijima K, et al. Molecular diagnosis and clinical onset of
Charcot-Marie-Tooth disease in Japan. J Hum Genet 2011;56:364–8.
22 Birouk N. [Charcot-Marie-Tooth disease]. Presse Med 2009;38:
200–9.
23 Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy
score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst
2011;16:191–8.
24 Tousignant R, Trepanier A, Shy ME, et al. Genetic testing practices for
Charcot-Marie-Tooth type 1A disease. Muscle Nerve 2014;49:
478–82.
25 Sadjadi R, Shy M, Reilly M, et al. Psychometric evaluation of Charcot-Marie-Tooth
disease (CMT) neuropathy score CMTNS) version 2.0 using Rasch analysis (Abstract).
J Peripher Nerv Syst 2014 Nov 14. doi:10.1111/jns.12084
26 Burns J, Ouvrier R, Estilow T, et al. Validation of the Charcot-Marie-Tooth disease
pediatric scale as an outcome measure of disability. Ann Neurol 2012;71:
642–52.
27 Ramchandren S, Shy M, Feldman E, et al. Deﬁning disability: patient and health
care provider perspectives in Charcot Marie Tooth disease. J Neurol Neurosurg
Psychiatry Published Online First: 25 Aug 2014. doi:10.1136/jnnp-2013-307390
28 Thomas PK, Marques W, Davis MB, et al. The phenotypic manifestations of
chromosome 17p11.2 duplication. Brain 1997;120:465–78.
29 Scherer SS, Kleopa KA. X-linked Charcot-Marie-Tooth disease. J Peripher Nerv Syst
2012;17(Suppl 3):9–13.
30 Siskind CE, Murphy SM, Ovens R, et al. Phenotype expression in women with
CMT1X. J Peripher Nerv Syst 2011;16:102–7.
6 Fridman V, et al. J Neurol Neurosurg Psychiatry 2014;0:1–6. doi:10.1136/jnnp-2014-308826
Neurogenetics
group.bmj.com on February 6, 2015 - Published by http://jnnp.bmj.com/Downloaded from 
cross-sectional analysis
Consortium natural history study: a
enrolled in the Inherited Neuropathies 
CMT subtypes and disease burden in patients
Shy and on behalf of the Inherited Neuropathies Consortium
E Siskind, S W Yum, I Moroni, E Pagliano, S Zuchner, S S Scherer, M E 
Lloyd, C J Sumner, F Muntoni, G Piscosquito, S Ramchandren, R Shy, C
Feely, R S Finkel, T Grider, C A Kirk, D N Herrmann, M Laurá, J Li, T 
V Fridman, B Bundy, M M Reilly, D Pareyson, C Bacon, J Burns, J Day, S
 published online November 27, 2014J Neurol Neurosurg Psychiatry 
 http://jnnp.bmj.com/content/early/2014/11/27/jnnp-2014-308826
Updated information and services can be found at: 
These include:
Material
Supplementary
 html
http://jnnp.bmj.com/content/suppl/2014/11/27/jnnp-2014-308826.DC1.
Supplementary material can be found at: 
References
 #BIBLhttp://jnnp.bmj.com/content/early/2014/11/27/jnnp-2014-308826
This article cites 26 articles, 3 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (594)Peripheral nerve disease
 (1193)Neuromuscular disease
 (149)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on February 6, 2015 - Published by http://jnnp.bmj.com/Downloaded from 
